Impact of smoking on response to systemic treatment in patients with psoriasis: A retrospective case-control study

British Journal of Dermatology

Volumn 172, Issue 2, 2015, Pages 428-436

  Kinahan, C E ^a   Mazloom, S ^b   Fernandez, A P ^b  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CYCLOSPORIN A; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; USTEKINUMAB; DERMATOLOGICAL AGENT;

ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RETROSPECTIVE STUDY; SMOKING; SMOKING CESSATION; SYSTEMIC THERAPY; ADOLESCENT; ADVERSE EFFECTS; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; DERMATOLOGIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; RETROSPECTIVE STUDIES; SMOKING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84922819280     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13359     Document Type: Article

References (40)

1. Griffiths CE, Barker JN,. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263-71.
2. Garg A, Gladman D,. Recognizing psoriatic arthritis in the dermatology clinic. J Am Acad Dermatol 2010; 63: 733-48.
3. Spah F,. Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach. Br J Dermatol 2008; 159: 10-17.
4. Kremers HM, McEvoy MT, Dann FJ, Gabriel SE,. Heart disease in psoriasis. J Am Acad Dermatol 2007; 57: 347-54.
5. Mehta NN, Saboury B, Foroughi N, et al,. Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot study. Arch Dermatol 2011; 147: 1031-9.
6. Gelfand JM, Dommasch ED, Shin DB, et al,. The risk of stroke in patients with psoriasis. J Invest Dermatol 2009; 129: 2411-18.
7. Friedewald VE, Cather JC, Gelfand JM, et al,. AJC editor's consensus: psoriasis and coronary artery disease. Am J Cardiol 2008; 102: 1631-43.
8. Naldi L,. Cigarette smoking and psoriasis. Clin Dermatol 1998; 16: 571-4.
9. Li W, Han J, Choi HK, Qureshi AA,. Smoking and risk of incident psoriasis among women and men in the United States: a combined analysis. Am J Epidemiol 2012; 175: 402-13.
10. Wolk K, Mallbris L, Larsson P, et al,. Excessive body weight and smoking associates with a high risk of onset of plaque psoriasis. Acta Derm Venereol 2009; 89: 492-7.
11. Huerta C, Rivero E, Rodríguez LA,. Incidence and risk factors for psoriasis in the general population. Arch Dermatol 2007; 143: 1559-65.
12. Gupta MA, Gupta AK, Watteel GN,. Cigarette smoking in men may be a risk factor for increased severity of psoriasis of the extremities. Br J Dermatol 1996; 135: 859-60.
13. Herron MD, Hinckley M, Hoffman MS, et al,. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005; 141: 1527-34.
14. Higgins EM, Chew E, Ward R, Peters TJ,. Antioxidant levels in psoriasis. Clin Sci 1994; 86 (Suppl. 30): 27.
15. Arnson Y, Shoenfeld Y, Amital H,. Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun 2010; 34: J258-65.
16. Robinson A, Kardos M, Kimball AB,. Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. J Am Acad Dermatol 2012; 66: 369-75.
17. Serwin AB, Sokolowska M, Chodynicka B,. Tumor necrosis factor-alpha-converting enzyme as a potential mediator of the influence of smoking on the response to treatment with narrowband ultraviolet B in psoriasis patients. Photodermatol Photoimmunol Photomed 2010; 26: 36-40.
18. Attwa E, Swelam E,. Relationship between smoking-induced oxidative stress and the clinical severity of psoriasis. J Eur Acad Dermatol Venereol 2011; 25: 782-7.
19. Setty AR, Curhan G, Choi HK,. Smoking and the risk of psoriasis in women: Nurses' Health Study II. Am J Med 2007; 120: 953-9.
20. Yildirim M, Inaloz HS, Baysal V, et al,. The role of oxidants and antioxidants in psoriasis. J Eur Acad Dermatol Venereol 2003; 17: 34-6.
21. Van der Haart H, Postma DS, Timens W, et al,. Acute effects of cigarette smoke on inflammation and oxidative stress: a review. Thorax 2004; 59: 713-21.
22. Arican O, Aral M, Sasmaz S, et al,. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm 2005; 2005: 273-9.
23. Torii K, Saito C, Furuhashi T, et al,. Tobacco smoke is related to Th17 generation with clinical implications for psoriasis patients. Exp Dermatol 2011; 20: 367-76.
24. Abhishek A, Butt S, Gadsby K, et al,. Anti-TNF-α agents are less effective for the treatment of rheumatoid arthritis in current smokers. J Clin Rheumatol 2010; 16: 15-18.
25. Saevarsdottir S, Wallin H, Seddighzadeh M, et al,. Predictors of response to methotrexate in early DMARD naïve rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial. Ann Rheum Dis 2011; 70: 469-75.
26. Westhoff G, Rau R, Zink A,. Rheumatoid arthritis patients who smoke have a higher need for DMARDs and feel worse, but they do not have more joint damage than non-smokers of the same serological group. Rheumatology (Oxford) 2008; 47: 849-54.
27. Soderlin MK, Petersson IF, Gaborek P,. The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug. Scand J Rheumatol 2012; 41: 1-9.
28. Hyrich KL, Watson KD, Silman AJ, et al,. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2006; 45: 1558-65.
29. Di Lernia V, Ricci C, Lallas A, Ficarelli E,. Clinical predictors of non-response to any tumor necrosis factor (TNF) blockers: a retrospective study. J Dermatolog Treat 2014; 25: 73-4.
30. Douwes KE, Karrer S, Abels C, et al,. Does smoking influence the efficacy of bath-PUVA therapy in chronic palmoplantar eczema? Photodermatol Photoimmunol Photomed 2000; 16: 25-9.
31. Ueno M, Ferreiro JL, Desai B, et al,. Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease. JACC Cardiovasc Interv 2012; 5: 293-300.
32. Grygiel JJ, Birkett DJ,. Cigarette smoking and theophylline clearance and metabolism. Clin Pharmacol Ther 1981; 30: 491-6.
33. Backman JT, Schroder MT, Neuvonen PJ,. Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine. Eur J Clin Pharmacol 2008; 64: 17-24.
34. Perel JM, Mendlewicz J, Shostak M, et al,. Plasma levels of imipramine in depression. Environmental and genetic factors. Neuropsychobiology 1976; 2: 193-202.
35. Hammond DK, Bjercke RJ, Langone JI, Strobel HW,. Metabolism of nicotine by rat liver cytochromes P-450. Assessment utilizing monoclonal antibodies to nicotine and cotinine. Drug Metab Dispos 1991; 19: 804-8.
36. Stamp LK, O'Donnell JL, Chapman PT, et al,. Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment. Arthritis Rheum 2009; 60: 2248-56.
37. Kronbach T, Fischer V, Meyer UA,. Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 1988; 43: 630-5.
38. Wojnowski L,. Genetics of the variable expression of CYP3A in humans. Ther Drug Monit 2004; 26: 192-9.
39. Ziegler UE, Kauczok J, Dietz UA, et al,. Clinical correlation between the consumption of nicotine and cotinine concentrations in urine and serum by competitive enzyme-linked immunosorbent assay. Pharmacology 2004; 72: 254-9.
40. Maska LB, Sayles HR, O'Dell JR, et al,. Serum cotinine as a biomarker of tobacco exposure and the association with treatment response in early rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64: 1804-10.